<![CDATA[This article examines this phenomenon through the global transition from iron–folic acid supplementation to antenatal multiple micronutrient supplements (MMS), using Indonesia as a critical contemporary case. It introduces the concept of a normative-material corridor: a governance structure in which authoritative scientific standards, evidence hierarchies, financing mechanisms, product availability, procurement support, technical assistance, and monitoring processes collectively narrow the range of practically available national policy choices. The corridor does not eliminate state sovereignty or legally mandate adoption. Instead, it makes one policy option progressively more legitimate, feasible, and administratively actionable than its alternatives. Using doctrinal analysis and socio-legal document analysis, this article traces the development of the MMS standard, the translation of World Health Organization authority into policy influence, the expanding role of philanthropic and catalytic capital, and the domestic implementation of these forces through Indonesian health, administrative, budgetary, and procurement frameworks. The analysis demonstrates that legal responsibility remains concentrated within the state, even when agenda setting, evidence generation, and material capacity are distributed among transnational actors. Indonesia therefore appears neither as a passive policy recipient nor as an entirely unconstrained sovereign actor, but rather as an agent exercising structured agency within a policy field whose prevailing conditions have already been shaped. To address the resulting accountability gap, this article proposes six safeguards: domestic legal translation, public reason-giving, financial and relational transparency, adaptive review mechanisms, a systems obligation against the reduction of stunting management to tablet-based interventions, and a distributed accountability matrix. MMS consequently reveals a broader challenge for medical law: how to govern forms of power that are non-coercive in appearance but regulatory in effect.]]>
Copyrights © 2026
